Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.

about

Harnessing Invariant NKT Cells to Improve Influenza Vaccines: A Pig Perspective.Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture.The Influence of Invariant Natural Killer T Cells on Humoral Immunity to T-Dependent and -Independent Antigens.

P2860

Q48343602-B2F6197F-A7C3-43FC-9D66-F6B3D62887CF Q50308620-DDFEAC28-C16F-4DD0-B32F-BFDBE5A0EAA5 Q50531631-68B25BC7-ADF1-4354-A3CD-9CBC246A81AB

P2860

Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.

Item

http://www.wikidata.org/entity/Q38719567

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Adjuvant use of the NKT cell a ...... ity against influenza A virus.

@en

type

Item

label

Adjuvant use of the NKT cell a ...... ity against influenza A virus.

@en

prefLabel

Adjuvant use of the NKT cell a ...... ity against influenza A virus.

@en

P1476

Adjuvant use of the NKT cell a ...... ity against influenza A virus.

@en

P2093

Ali Gorji

http://www.w3.org/2001/XMLSchema#string

Alijan Tabarraei

http://www.w3.org/2001/XMLSchema#string

Amir Ghaemi

http://www.w3.org/2001/XMLSchema#string

Behrokh Farahmand

http://www.w3.org/2001/XMLSchema#string

Fatemeh Fotouhi

http://www.w3.org/2001/XMLSchema#string

Mina Shaffifar

http://www.w3.org/2001/XMLSchema#string

Mohsen Saeidi

http://www.w3.org/2001/XMLSchema#string

Sadegh Shirian

http://www.w3.org/2001/XMLSchema#string

P2860

NKT cell subsets as key participants in liver physiology and pathology

Balancing Immune Protection and Immune Pathology by CD8(+) T-Cell Responses to Influenza Infection

M2e-Based Universal Influenza A Vaccines

NKT cell networks in the regulation of tumor immunity

Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study

Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans

Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development

Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus.

All-in-one bacmids: an efficient reverse genetics strategy for influenza A virus vaccines.

Global burden of influenza as a cause of cardiopulmonary morbidity and mortality

P2888

s00705-017-3230-7

P304

1251-1260

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00705-017-3230-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

162

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1074204430

http://www.w3.org/2001/XMLSchema#string

P698

28120096

http://www.w3.org/2001/XMLSchema#string

Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.

about

P2860

P2860

Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698